A role for m6A RNA methylation in heart failure development?

Devaux, Yvan; Nossent, A. Yaël

doi:10.1002/ejhf.1714

Cited by 9 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 16 Moreover, overexpression of FTO is capable of reversing cardiac fibrosis and inducing angiogenesis in the heart failure post MI. 16 In summary, m6A is considered to be critical in the development of heart failure, 129 and more researches are need to demonstrate its therapeutic effect.…”

Section: Cardiac Hypertrophy and Heart Failurementioning

confidence: 99%

The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases

et al. 2021

View full text Add to dashboard Cite

N6-methyladenosine (m6A) RNA methylation is an emerging area of epigenetics, which is a reversible and dynamic modification mediating by ‘writers’ (methylase, adding methyl groups, METTL3, METTL14, and WTAP), ‘erasers’ (demethylase, deleting methyl groups, FTO and ALKBH5), and ‘readers’ (YTHDF1-3, YTHDC1 and YTHDC2). Recent studies in human, animal models and cell levels have disclosed a critical role of m6A modification in regulating the homeostasis of metabolic processes and cardiovascular function. Evidence from these studies identify m6A as a candidate of biomarker and therapeutic target for metabolic abnormality and cardiovascular diseases (CVD). Comprehensive understanding of the complexity of m6A regulation in metabolic diseases and CVD will be helpful for us to understand the pathogenesis of CVD. In this review, we discuss the regulatory role of m6A in metabolic abnormality and CVD. We will emphasize the clinical relevance of m6A dysregulation in CVD.

show abstract

Section: Cardiac Hypertrophy and Heart Failurementioning

confidence: 99%

The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases

et al. 2021

View full text Add to dashboard Cite

show abstract

“…m6A RNA methylation is involved in diverse biological processes, such as differentiation and pluripotency of stem cells, embryogenesis, DNA damage response as well as the transcription, alternative splicing, nuclear export, translation and degradation of mRNAs ( Batista et al, 2014 ; Xiang et al, 2017 ; Zhao et al, 2017 ; Sun et al, 2019 ). More and more studies have shown that abnormal m6A RNA methylation plays a crucial role in the pathogenesis of many human diseases including cancers ( Liu et al, 2018 ; De Jesus et al, 2019 ; Devaux and Nossent, 2019 ; Gokhale et al, 2019 ; Liu X. et al, 2019 ). However, little is known about m6A RNA methylation in lung adenocarcinoma.…”

Section: Introductionmentioning

confidence: 99%

m6A RNA Methylation Regulators Participate in the Malignant Progression and Have Clinical Prognostic Value in Lung Adenocarcinoma

Wang

Huang

et al. 2020

Front. Genet.

View full text Add to dashboard Cite

Abnormal methylation of N6 adenosine (m6A) in RNA plays a crucial role in the pathogenesis of many types of tumors. However, little is known about m6A RNA methylation in lung adenocarcinoma. This study aimed to identify the value of m6A RNA methylation regulators in the malignant progression and clinical prognosis of lung adenocarcinoma. The RNA-seq transcriptome data and corresponding clinical information of lung adenocarcinoma were downloaded from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) database. Then the identification of differentially expressed m6A RNA methylation regulators between cancer samples and normal control samples, different subgroups by consensus expression of these regulators and the prognostic signature were achieved using R software with multiple corresponding packages. The results showed that the expression levels of HNRNPC, YTHDF1, KIAA1429, RBM15, YTHDF2, and METTL3 in cancer group were significantly up-regulated ( P < 0.05), while expression levels of FTO, ZC3H13, METTL14, YTHDC1 and WTAP in cancer group were significantly down-regulated ( P < 0.05) compared with control group. Two subgroups identified by consensus expression of these regulators were closely related to the clinicopathological features, clinical outcomes and malignancy of lung adenocarcinoma. In addition, a 3-gene risk signature including KIAA1429, RBM15, and HNRNPC was constructed and the lung adenocarcinoma patients in TCGA database were divided into high-risk group and low-risk group based on the median risk score. In conclusion, the prognostic signature-based risk score calculated according to the expression levels of KIAA1429, RBM15, and HNRNPC, was not only strongly associated with clinical outcomes and clinicopathological features, but also an independent prognostic factor in lung adenocarcinoma.

show abstract

“…m6a modifications and HF m6A RNA modification is involved in the regulation of environmental homeostasis in the cardiovascular system and the pathophysiological process of various cardiovascular diseases, regulating the stability of mRNA and changes in protein expression (53). Regulation of m6A modification of various homeostasis regulators is conducted at the posttranscriptional level, and this regulation mode responds rapidly to external signaling molecules and stimuli.…”

Section: M6a and Lncrnamentioning

confidence: 99%

N6-methyladenosine (m6A) RNA modification in the pathophysiology of heart failure: a narrative review

Liu¹,

Wang²,

Cheng³

et al. 2022

Cardiovasc Diagn Ther

View full text Add to dashboard Cite

Background and Objective: Heart failure is the end-stage of various cardiovascular diseases.Recent progress in molecular biology has facilitated the understanding of the mechanisms of heart failure development at the molecular level. N6-adenosine methylation (m6A) is a post-transcriptional modification of RNA. Recent research work reported that m6A regulates gene expression and subsequently affects the activation of cell signaling pathways related to heart failure. Moreover, m6A regulators like methyltransferase-like 3 (METTL3) were reported to participate in myocardium hypertrophy. However, the current research work related to the role of m6A participating in the occurrence of heart failure is rare in some aspects like immune cell infiltration and diabetic heart diseases. Thus, it is reasonable to review the current achievements and provide further study orientation. Methods:We searched related literature using the keywords: m6A AND heart failure in PubMed, Web of Science and Medline. The language was confined to English. The published year of searched literature ranged from 2012 to 2022. The searched results were put into Endnote software for management. Two authors investigated the searching terms and reviewed the full text of selected terms.Key Content and Findings: m6A and its regulators are involved in the metabolism of various types of RNAs. m6A modification can regulate various types of cell signaling pathways related to the heart failure via interaction with m6A regulators. m6A and its regulators broadly participate in the myocardium fibrosis, myocardium hypertrophy, myocardial cell apoptosis, and ischemic reperfusion injury. Specifically, m6A participates in the cell apoptosis via regulation of autophagy flux. However, the current research work does not have enough evidence to prove that m6A regulator played its specific effect on the target transcript via regulating the m6A level.Conclusions: m6A and its regulators participates in the progression of heart failure via modifying the RNA level. Future investigation of m6A should focus on the interaction between the m6A regulators and targeted transcript. Besides, the regulation role of m6A in immune cell infiltration and diabetic heart diseases should also be focused.

show abstract

A role for m6A RNA methylation in heart failure development?

Cited by 9 publications

References 16 publications

The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases

The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases

m6A RNA Methylation Regulators Participate in the Malignant Progression and Have Clinical Prognostic Value in Lung Adenocarcinoma

N6-methyladenosine (m6A) RNA modification in the pathophysiology of heart failure: a narrative review

Contact Info

Product

Resources

About